Taysha Gene Therapies (TSHA) Return on Sales (2023 - 2026)

Taysha Gene Therapies (TSHA) has 4 years of Return on Sales data on file, last reported at 0.74% in Q1 2026.

• For the quarter ending Q1 2026, Return on Sales fell 62.0% year-over-year to 0.74%; the trailing twelve-month figure through Mar 2026 stood at 0.74% (down 57.0% YoY), and the FY2025 full-year result was 0.33%, down 9.0% from the prior year.
• Return on Sales slipped to 0.74% in Q1 2026, from 0.21% in the prior quarter.
• In the past five years, Return on Sales ranged from a high of 0.04% in Q4 2023 to a low of 0.74% in Q1 2026.
• A 4-year average of 0.21% and a median of 0.21% in 2025 frame the typical range for Return on Sales.
• Across the five-year window, Return on Sales gained 5 bps in 2025 and plunged 62 bps in 2026, its largest moves.
• Tracing TSHA's Return on Sales over 4 years: stood at 0.04% in 2023, then sank by 64 bps to 0.07% in 2024, then tumbled by 196 bps to 0.21% in 2025, then tumbled by 253 bps to 0.74% in 2026.
• Business Quant data shows TSHA's Return on Sales at 0.74% in Q1 2026, 0.21% in Q4 2025, and 0.25% in Q3 2025.